{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:37:24Z","timestamp":1777394244590,"version":"3.51.4"},"reference-count":57,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2016,5,23]]},"DOI":"10.3233\/jad-151015","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T12:00:10Z","timestamp":1464091210000},"page":"831-841","source":"Crossref","is-referenced-by-count":9,"title":["Insight into the Dissociation of Behavior from Histology in Synucleinopathies and in Related Neurodegenerative Diseases"],"prefix":"10.1177","volume":"52","author":[{"given":"Kazunari","family":"Sekiyama","sequence":"first","affiliation":[{"name":"Tokyo Metropolitan Institute of Medical Sciences, Setagaya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Institute of Medical Sciences, Setagaya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wakako","family":"Koike","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Institute of Medical Sciences, Setagaya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Waragai","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Institute of Medical Sciences, Setagaya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takato","family":"Takenouchi","sequence":"additional","affiliation":[{"name":"Division of Animal Sciences, National Institute of Agrobiological Sciences, Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuei","family":"Sugama","sequence":"additional","affiliation":[{"name":"Department of Physiology, Nippon Medical School, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Institute of Medical Sciences, Setagaya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-151015_ref1","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.1228541","article-title":"Preventing Alzheimer\u2019s disease","volume":"337","author":"Selkoe","year":"2012","journal-title":"Science"},{"key":"10.3233\/JAD-151015_ref2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0010-9452(08)70489-1","article-title":"A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer\u2019s disease and Parkinson\u2019s disease with dementia","volume":"43","author":"Metzler-Baddeley","year":"2007","journal-title":"Cortex"},{"key":"10.3233\/JAD-151015_ref3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbrc.2014.06.028","article-title":"Role of genomics in translational research for Parkinson\u2019s disease","volume":"452","author":"Sekiyama","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3233\/JAD-151015_ref4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bcp.2013.12.020","article-title":"Immunotherapy for Alzheimer\u2019s disease","volume":"88","author":"Wisniewski","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.3233\/JAD-151015_ref5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev-pharmtox-010814-124309","article-title":"Learning by failing: Ideas and concepts to tackle gamma-secretases in Alzheimer\u2019s disease and beyond","volume":"55","author":"De Strooper","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.3233\/JAD-151015_ref6","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/brain\/awq056","article-title":"Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology","volume":"133","author":"Serrano-Pozo","year":"2010","journal-title":"Brain"},{"key":"10.3233\/JAD-151015_ref7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neulet.2012.03.037","article-title":"Ibuprofen ameliorates protein aggregation and astrocytic gliosis, but not cognitive dysfunction, in a transgenic mouse expressing dementia with Lewy bodies-linked P123H beta-synuclein","volume":"515","author":"Sekiyama","year":"2012","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-151015_ref8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0197-4580(92)90027-U","article-title":"Identification of normal and pathological aging in prospectively studied nondemented elderly humans","volume":"13","author":"Dickson","year":"1992","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-151015_ref9","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(94)92854-1","article-title":"Incidental Lewy body disease in black Africans","volume":"344","author":"Jendroska","year":"1994","journal-title":"Lancet"},{"key":"10.3233\/JAD-151015_ref10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.3233\/JAD-151015_ref11","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"10.3233\/JAD-151015_ref12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jalz.2012.04.007","article-title":"Worldwide Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"8","author":"Carrillo","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-151015_ref13","unstructured":"(2011) The Parkinson Progression Marker Initiative. (PPMI). Prog Neurobiol 95, 629\u2013635."},{"key":"10.3233\/JAD-151015_ref14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/alzrt213","article-title":"Dominantly Inherited Alzheimer Network: Facilitating research and clinical trials","volume":"5","author":"Moulder","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-151015_ref15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Alzheimer\u2019s Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-151015_ref16","doi-asserted-by":"crossref","first-page":"h4528","DOI":"10.1136\/bmj.h4528","article-title":"Recent trial shows that solanezumab has disease modifying effects","volume":"351","author":"Karran","year":"2015","journal-title":"BMJ"},{"key":"10.3233\/JAD-151015_ref17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer\u2019s disease patients","volume":"12","author":"Siemers","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-151015_ref18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2183\/pjab.90.301","article-title":"Lewy body disease and dementia with Lewy bodies","volume":"90","author":"Kosaka","year":"2014","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.3233\/JAD-151015_ref19","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JAD-151015_ref20","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","article-title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease","volume":"90","author":"Ueda","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-151015_ref21","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0002-9440(10)65722-7","article-title":"Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer\u2019s disease patients with mutations in presenilin and amyloid precursor protein genes","volume":"153","author":"Lippa","year":"1998","journal-title":"Am J Pathol"},{"key":"10.3233\/JAD-151015_ref22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","article-title":"Lewy bodies in Alzheimer\u2019s disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry","volume":"10","author":"Hamilton","year":"2000","journal-title":"Brain Pathol"},{"key":"10.3233\/JAD-151015_ref23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","article-title":"International Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies","volume":"3","author":"McKeith","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-151015_ref24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1196\/annals.1332.005","article-title":"NSAID and antioxidant prevention of Alzheimer\u2019s disease: Lessons from in vitro and animal models","volume":"1035","author":"Cole","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-151015_ref25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/1567205054367883","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease","volume":"2","author":"Klegeris","year":"2005","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-151015_ref26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ncomms1101","article-title":"A beta-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain","volume":"1","author":"Fujita","year":"2010","journal-title":"Nat Commun"},{"key":"10.3233\/JAD-151015_ref27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/01.WNL.0000139870.14385.3C","article-title":"Beta-synuclein gene alterations in dementia with Lewy bodies","volume":"63","author":"Ohtake","year":"2004","journal-title":"Neurology"},{"key":"10.3233\/JAD-151015_ref28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1756-6606-5-34","article-title":"Distinct mechanisms of axonal globule formation in mice expressing human wild type alpha-synuclein or dementia with Lewy bodies-linked P123H beta-synuclein","volume":"5","author":"Sekigawa","year":"2012","journal-title":"Mol Brain"},{"key":"10.3233\/JAD-151015_ref29","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1523\/JNEUROSCI.20-15-05709.2000","article-title":"Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer\u2019s disease","volume":"20","author":"Lim","year":"2000","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-151015_ref30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0197-4580(01)00299-8","article-title":"Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice","volume":"22","author":"Lim","year":"2001","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-151015_ref31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.brainres.2008.01.095","article-title":"Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice","volume":"1207","author":"McKee","year":"2008","journal-title":"Brain Res"},{"key":"10.3233\/JAD-151015_ref32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity","volume":"414","author":"Weggen","year":"2008","journal-title":"Nature"},{"key":"10.3233\/JAD-151015_ref33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0896-6273(03)00024-2","article-title":"The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson\u2019s disease","volume":"37","author":"Sharon","year":"2003","journal-title":"Neuron"},{"key":"10.3233\/JAD-151015_ref34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12035-012-8251-3","article-title":"A\u03b2 toxicity in Alzheimer\u2019s disease","volume":"45","author":"Cavallucci","year":"2012","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-151015_ref35","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2353\/ajpath.2009.080680","article-title":"Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies","volume":"174","author":"Wei","year":"2009","journal-title":"Am J Pathol"},{"key":"10.3233\/JAD-151015_ref36","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jalz.2012.11.012","article-title":"Results of a follow-up study to the randomized Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial (ADAPT)","volume":"9","author":"Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial Research Group","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-151015_ref37","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/brain\/awt171","article-title":"Dissecting phenotypic traits linked to human resilience to Alzheimer\u2019s pathology","volume":"136","author":"Perez-Nievas","year":"2013","journal-title":"Brain"},{"key":"10.3233\/JAD-151015_ref38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ana.410230206","article-title":"Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques","volume":"23","author":"Katzman","year":"1988","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-151015_ref39","first-page":"1033","article-title":"[Incidental occurrence of Lewy bodies in the brains of elderly patients\u2013the relevance to aging and Parkinson\u2019s disease]","volume":"45","author":"Wakabayashi","year":"1993","journal-title":"Brain"},{"key":"10.3233\/JAD-151015_ref40","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00401-007-0313-7","article-title":"Reduced striatal tyrosine hydroxylase in incidental Lewy body disease","volume":"115","author":"Beach","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-151015_ref41","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.semcdb.2011.03.011","article-title":"Amyloid in neurodegenerative diseases: Friend or foe?","volume":"22","author":"Wolfe","year":"2011","journal-title":"Semin Cell Dev Biol"},{"key":"10.3233\/JAD-151015_ref42","doi-asserted-by":"crossref","first-page":"8972","DOI":"10.1021\/bi9904149","article-title":"Assembly of A beta amyloid protofibrils: An in vitro model for a possible early event in Alzheimer\u2019s disease","volume":"38","author":"Harper","year":"1999","journal-title":"Biochemistry"},{"key":"10.3233\/JAD-151015_ref43","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.neuropharm.2007.11.010","article-title":"Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro","volume":"54","author":"Hirohata","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-151015_ref44","doi-asserted-by":"crossref","first-page":"28737","DOI":"10.1074\/jbc.M115.675215","article-title":"Structural mechanism of the interaction of Alzheimer\u2019s disease A\u03b2 fibrils with the NSAID sulindac sulfide","volume":"290","author":"Prade","year":"2015","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-151015_ref45","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S1474-4422(12)70191-6","article-title":"Cognitive reserve in ageing and Alzheimer\u2019s disease","volume":"11","author":"Stern","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-151015_ref46","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(15)00144-1","article-title":"Pioglitazone in early Parkinson\u2019s disease: A phase 2, multicentre, double-blind, randomised trial","volume":"14","author":"NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-151015_ref47","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00018-015-2101-1","article-title":"Current disease modifying approaches to treat Parkinson\u2019s disease","volume":"73","author":"Lindholm","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.3233\/JAD-151015_ref48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial","volume":"6","author":"Gordon","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-151015_ref49","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1212\/01.WNL.0000142992.81995.F0","article-title":"A clinical trial of creatine in ALS","volume":"63","author":"Shefner","year":"2004","journal-title":"Neurology"},{"key":"10.3233\/JAD-151015_ref50","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archneur.1994.00540200048015","article-title":"Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia","volume":"51","author":"Samuel","year":"1994","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-151015_ref51","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2174\/156720509789207930","article-title":"Tau-focused immunotherapy for Alzheimer\u2019s disease and related tauopathies","volume":"6","author":"Sigurdsson","year":"2009","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-151015_ref52","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","article-title":"Tau immunotherapy for Alzheimer\u2019s disease","volume":"21","author":"Pedersen","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.3233\/JAD-151015_ref53","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson\u2019s disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"10.3233\/JAD-151015_ref54","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"10.3233\/JAD-151015_ref55","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4093\/dmj.2015.39.5.363","article-title":"Perspective of small-molecule AdipoR agonist for type 2 diabetes and short life in obesity","volume":"39","author":"Okada-Iwabu","year":"2015","journal-title":"Diabetes Metab J"},{"key":"10.3233\/JAD-151015_ref56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/acn3.77","article-title":"Disease-modifying effect of adiponectin in model of alpha-synucleinopathies","volume":"1","author":"Sekiyama","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JAD-151015_ref57","doi-asserted-by":"crossref","first-page":"11708","DOI":"10.1038\/srep11708","article-title":"Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus","volume":"5","author":"Ali","year":"2015","journal-title":"Sci Rep"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-151015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:02:45Z","timestamp":1777370565000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-151015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,23]]},"references-count":57,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-151015","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,23]]}}}